Towards a nanoparticle-based prophylactic for maternal autoantibody-related autism

Amir Bolandparvaz, Rian Harriman, Kenneth Alvarez, Kristina Lilova, Zexi Zang, Andy Lam, Elizabeth Edmiston, Alexandra Navrotsky, Natalia Vapniarsky Arzi, Judith A Van de Water, Jamal S. Lewis

Research output: Contribution to journalArticle

Abstract

Recently, the causative agents of Maternal Autoantibody-Related (MAR) autism, pathological autoantibodies and their epitopic targets (e.g. lactate dehydrogenase B [LDH B] peptide), have been identified. Herein, we report on the development of Systems for Nanoparticle-based Autoantibody Reception and Entrapment (SNAREs), which we hypothesized could scavenge disease-propagating MAR autoantibodies from the maternal blood. To demonstrate this functionality, we synthesized 15 nm dextran iron oxide nanoparticles surface-modified with citric acid, methoxy PEG(10 kDa) amine, and LDH B peptide (33.8 μg peptide/cm2). In vitro, we demonstrated significantly lower macrophage uptake for SNAREs compared to control NPs. The hallmark result of this study was the efficacy of the SNAREs to remove 90% of LDH B autoantibody from patient-derived serum. Further, in vitro cytotoxicity testing and a maximal tolerated dose study in mice demonstrated the safety of the SNARE formulation. This work establishes the feasibility of SNAREs as the first-ever prophylactic against MAR autism.

Original languageEnglish (US)
Article number102067
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume21
DOIs
StatePublished - Oct 1 2019

Fingerprint

Autistic Disorder
Autoantibodies
Nanoparticles
Mothers
Peptides
Dextran
Maximum Tolerated Dose
Macrophages
Citric acid
Cytotoxicity
Dextrans
Iron oxides
Citric Acid
Polyethylene glycols
Amines
Blood
Safety

Keywords

  • Iron oxide
  • Maternal autoantibody-related autism
  • nanoparticles
  • Peptide-functionalized

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Cite this

Bolandparvaz, A., Harriman, R., Alvarez, K., Lilova, K., Zang, Z., Lam, A., ... Lewis, J. S. (2019). Towards a nanoparticle-based prophylactic for maternal autoantibody-related autism. Nanomedicine: Nanotechnology, Biology, and Medicine, 21, [102067]. https://doi.org/10.1016/j.nano.2019.102067

Towards a nanoparticle-based prophylactic for maternal autoantibody-related autism. / Bolandparvaz, Amir; Harriman, Rian; Alvarez, Kenneth; Lilova, Kristina; Zang, Zexi; Lam, Andy; Edmiston, Elizabeth; Navrotsky, Alexandra; Vapniarsky Arzi, Natalia; Van de Water, Judith A; Lewis, Jamal S.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 21, 102067, 01.10.2019.

Research output: Contribution to journalArticle

Bolandparvaz, Amir ; Harriman, Rian ; Alvarez, Kenneth ; Lilova, Kristina ; Zang, Zexi ; Lam, Andy ; Edmiston, Elizabeth ; Navrotsky, Alexandra ; Vapniarsky Arzi, Natalia ; Van de Water, Judith A ; Lewis, Jamal S. / Towards a nanoparticle-based prophylactic for maternal autoantibody-related autism. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2019 ; Vol. 21.
@article{58a38a2bffe3450f966fe2f1f8a77745,
title = "Towards a nanoparticle-based prophylactic for maternal autoantibody-related autism",
abstract = "Recently, the causative agents of Maternal Autoantibody-Related (MAR) autism, pathological autoantibodies and their epitopic targets (e.g. lactate dehydrogenase B [LDH B] peptide), have been identified. Herein, we report on the development of Systems for Nanoparticle-based Autoantibody Reception and Entrapment (SNAREs), which we hypothesized could scavenge disease-propagating MAR autoantibodies from the maternal blood. To demonstrate this functionality, we synthesized 15 nm dextran iron oxide nanoparticles surface-modified with citric acid, methoxy PEG(10 kDa) amine, and LDH B peptide (33.8 μg peptide/cm2). In vitro, we demonstrated significantly lower macrophage uptake for SNAREs compared to control NPs. The hallmark result of this study was the efficacy of the SNAREs to remove 90{\%} of LDH B autoantibody from patient-derived serum. Further, in vitro cytotoxicity testing and a maximal tolerated dose study in mice demonstrated the safety of the SNARE formulation. This work establishes the feasibility of SNAREs as the first-ever prophylactic against MAR autism.",
keywords = "Iron oxide, Maternal autoantibody-related autism, nanoparticles, Peptide-functionalized",
author = "Amir Bolandparvaz and Rian Harriman and Kenneth Alvarez and Kristina Lilova and Zexi Zang and Andy Lam and Elizabeth Edmiston and Alexandra Navrotsky and {Vapniarsky Arzi}, Natalia and {Van de Water}, {Judith A} and Lewis, {Jamal S.}",
year = "2019",
month = "10",
day = "1",
doi = "10.1016/j.nano.2019.102067",
language = "English (US)",
volume = "21",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Towards a nanoparticle-based prophylactic for maternal autoantibody-related autism

AU - Bolandparvaz, Amir

AU - Harriman, Rian

AU - Alvarez, Kenneth

AU - Lilova, Kristina

AU - Zang, Zexi

AU - Lam, Andy

AU - Edmiston, Elizabeth

AU - Navrotsky, Alexandra

AU - Vapniarsky Arzi, Natalia

AU - Van de Water, Judith A

AU - Lewis, Jamal S.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Recently, the causative agents of Maternal Autoantibody-Related (MAR) autism, pathological autoantibodies and their epitopic targets (e.g. lactate dehydrogenase B [LDH B] peptide), have been identified. Herein, we report on the development of Systems for Nanoparticle-based Autoantibody Reception and Entrapment (SNAREs), which we hypothesized could scavenge disease-propagating MAR autoantibodies from the maternal blood. To demonstrate this functionality, we synthesized 15 nm dextran iron oxide nanoparticles surface-modified with citric acid, methoxy PEG(10 kDa) amine, and LDH B peptide (33.8 μg peptide/cm2). In vitro, we demonstrated significantly lower macrophage uptake for SNAREs compared to control NPs. The hallmark result of this study was the efficacy of the SNAREs to remove 90% of LDH B autoantibody from patient-derived serum. Further, in vitro cytotoxicity testing and a maximal tolerated dose study in mice demonstrated the safety of the SNARE formulation. This work establishes the feasibility of SNAREs as the first-ever prophylactic against MAR autism.

AB - Recently, the causative agents of Maternal Autoantibody-Related (MAR) autism, pathological autoantibodies and their epitopic targets (e.g. lactate dehydrogenase B [LDH B] peptide), have been identified. Herein, we report on the development of Systems for Nanoparticle-based Autoantibody Reception and Entrapment (SNAREs), which we hypothesized could scavenge disease-propagating MAR autoantibodies from the maternal blood. To demonstrate this functionality, we synthesized 15 nm dextran iron oxide nanoparticles surface-modified with citric acid, methoxy PEG(10 kDa) amine, and LDH B peptide (33.8 μg peptide/cm2). In vitro, we demonstrated significantly lower macrophage uptake for SNAREs compared to control NPs. The hallmark result of this study was the efficacy of the SNAREs to remove 90% of LDH B autoantibody from patient-derived serum. Further, in vitro cytotoxicity testing and a maximal tolerated dose study in mice demonstrated the safety of the SNARE formulation. This work establishes the feasibility of SNAREs as the first-ever prophylactic against MAR autism.

KW - Iron oxide

KW - Maternal autoantibody-related autism

KW - nanoparticles

KW - Peptide-functionalized

UR - http://www.scopus.com/inward/record.url?scp=85070590101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070590101&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2019.102067

DO - 10.1016/j.nano.2019.102067

M3 - Article

VL - 21

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

M1 - 102067

ER -